GeneDose Medication Action Plan

Patient: Suretest, Doug	Created by: Coriell Life Sciences
Date of Birth: Mar 1, 1955	Pharmacist: Amy Miller
Gender: MALE	Phone: (888)415-7834
Patient Identifier: SMPL2	Email: info@coriell.com

1. About This Report

This GeneDose Medication Action Plan (MAP) is the result of a Medication Risk Assessment that consists of clinical pharmacogenomic assays that together with clinical, demographic, lifestyle information, and pharmacist's review provide a Medication Action Plan. Pharmaceutical safety, healthcare best practices, lifestyle factors, side effects, medical conditions, and more were analyzed.

The Pharmacist's Notes & Recommendations below provide clinical suggestions for your consideration.

2. Results

The Pharmacist's recommended changes to the patient's current medications are based on the Medication Risk Assessment.

Suggested Changes to Current Medications:

--- Remove (5) ---	+++ Add (4) +++	✓ ✓ ✓ Do not Change (4) ✓ ✓ ✓
1. Amiodarone Hydrochloride 2. Fluconazole 3. Sertraline Hydrochloride 4. Tacrolimus 5. Warfarin Sodium	1. Mexiletine Hydrochloride 2. Sirolimus 3. Vilazodone hydrochloride 4. Vorapaxar	1. Maraviroc 2. Metformin Hydrochloride 3. Metronidazole 4. Simvastatin

Pharmacist's Notes & Recommendations:

As per Results table: Change prograf, warfarin, sertraline to reduce risks associated with drug-drug interaction, genetic, and Beer's list. Reduce the safety exposure and risk of re-hospitalization for the transplant patient. It is assumed that patient compliance will improve through decrease in side effects, as well. Remove Diflucan, change amiodarone: Pt is already on Flagyl and a more appropriate drug would be the addition of a UTI antibiotic versus another antifungal; decreases DDI-related QT prolongation concerns.

3. Next Steps

Changes in medication dosing are recommended as noted in order to reduce risk of adverse reactions and potential therapy failures. Supplemental risk information can be found in Section 4.

4. Supplemental Information: Medication Risk Charts

These charts show each medication input into GeneDose Medication Risk Assessment for the patient. The longer a bar is in the chart, the more risky the medication may be.

Current Regimen



Pharmacist's Suggested Regimen



5. ApoE Genotype Information †

Tested Genes (Alleles)	Genotype	Predicted Phenotype	Clinical Guidance
ApoE (ε2, ε3, ε4)	ε3|ε3	Often associated with normal lipid metabolism.	Typical cardiovascular disease risk expected.

General Description

Genetic analysis in the ApoE gene was performed using molecular genetic techniques. The genotype is based on genotyping results for this patient at SNPs rs429358 and rs7412.

ApoE ε3 is the most common allele—found in about 60% of people. The presence of ε2 or ε4 alleles may be a risk factor for multiple conditions including cardiovascular disease. ApoE ε2 carriers may be more likely to develop familial dysbetalipoproteinemia or type III hyperlipoproteinemia.

† Predicted phenotype, clinical significance, relative risk, and interpretations reported for each genotype are associated with cardiovascular risk only. The interpretations should not be used to determine the relative risk of other diseases. Other factors important to understanding total risk should be considered.

6. Supplemental Information: Genotype Results and Clinical Implications

This genetic test only detects the genes listed below. A typical (normal; wild type) genotype signifies the absence of the targeted alleles and does not indicate the absence of other mutations not covered by the assay. These results are not intended as a replacement for the complete Coriell GeneDose Pharmacogenomics report and should be considered in context of medical history and current treatment regimen.

Gene	Reference	Result	Implication
OPRM1(A118G)	A|A	Not Tested	
CYP2C9:rs1057910	A|A	Not Tested	
TPMT	n/a	*1|*1	
FKBP5(rs1360780)	T/T	Not Tested	
GRIN2B(rs2058878)	T/T	Not Tested	
GRIK4	C|C	Not Tested	
HTR2A	A|A	Not Tested	
DBH(-1021C>T)	C/C	Not Tested	
CYP2C19	n/a	*1|*1	
CYP3A4	n/a	*1A|*1A	
CACNA1C(5361G>A)	G/G	Not Tested	
CYP3A5	n/a	*1A|*1A	
SLCO1B1	n/a	*1|*1	
CYP2B6	*1A|*1A	Not Tested	
CACNA1C(270344G>A)	G/G	Not Tested	
CYP2D6	*1|*1	*1|*1	Typical Function
ApoE	n/a	E3|E3	
GRIK1(rs2832407)	C/C	Not Tested	
VKORC1	n/a	*2|*2	
HTR2C(2565G>C)	G/G	Not Tested	
BDNF	C|C	Not Tested	
CYP4F2	*1|*1	Not Tested	
UGT2B15	*1|*1	Not Tested	
F5	n/a	T|T	
CYP2C9	n/a	*2|*3	
FKBP5(rs1902023)	A/A	Not Tested	
HTR2C(-759C>T)	C/C	Not Tested	
OPRK1(rs6473797)	T/T	Not Tested	
CYP1A2	*1A|*1A	Not Tested	
COMT(Val158Met)	G|G	Not Tested	
ADRA2A(C-1291G)	C|C	Not Tested	
ATM	A|A	A|A	Typical Function
HLA-B*1502	n/a	WT|WT	
ANKK1	G|G	Not Tested	
HLA-B*5701	n/a	WT|WT	

GeneDose Medication Action Plan

Gene	Reference	Result	Implication
OPRD1(rs678849)	C/C	Not Tested	
ABCG2	G|G	Not Tested	

Please note that "Uncertain" means that no known Result name or clinical Implication exists for this combination of genetic variants; Uninterpretable Genotype.